Integra LifeSciences Holdings Corp Stock News

Integra (IART) delivered earnings and revenue surprises of 23.21% and 2.92%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Shares of Integra Lifesciences (NASDAQ:IART) rose 1.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 43.75% over the past year to $0.69, w

PRINCETON, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the firs

The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

The acquisition of ACell, and faster recovery growth rate in Japan and China are likely to have helped recover Integra's first-quarter 2021 performance.

Here are five orthopedic device stocks, Integra (IART), Conformis (CFMS), SeaSpine (SPNE), Zimmer Biomet (ZBH), Orthofix (OFIX), which are expected to continue their run over the next few months.

Integra (IART) is optimistic about maintaining its strength in its international business, along with its portfolio optimization strategy.

PRINCETON, N.J., April 19, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company and manufacturer of SurgiMend Collagen Matrix,

PRINCETON, N.J., April 08, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2021 financial res

PRINCETON, N.J., April 01, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced the appointment of Shaundra C

Investors are optimistic about Integra LifeSciences (IART) stock, owing to its strong international business growth and focus on portfolio optimization.

Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically,

Recovering Trauma Cases Should Highlight AxoGen's Improving Execution

After the rise of 10-year yields terrified investors, the indices “reverse rotated” back into the Nasdaq and out of the Dow. Make the most of this market with today's top buys, from Q.ai's Artific

Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically.